PrognomiQ announced the initial launch of its ProVue blood test while Mercy presented new data detailing the performance of its Halo lung cancer test.
The firm's new strategy revolves around adding to its test menu in an impactful way and expanding its installed base of instruments.
NEW YORK – French precision psychiatry firm Alcediag is planning a European commercialization strategy for its test to differentiate between depression and bipolar disorder after launching in France, ...
NEW YORK – Abbott Laboratories announced Thursday that it will acquire cancer diagnostic firm Exact Sciences for an estimated enterprise value of $23 billion. Abbott will acquire all outstanding ...
NEW YORK – Gradientech announced Wednesday that it has submitted a 510(k) premarket notification to the US Food and Drug Administration for its QuickMIC antimicrobial susceptibility testing platform.
The company presented data at last week's AMP annual meeting proving the concept of its platform's applications in infectious disease and cancer.
A slew of new studies and reports suggest that new molecular approaches may soon help reduce the global burden of tuberculosis.
With the transaction, which Bloomberg News said could be announced within the next several days, Abbott would acquire tests including Exact's Cologuard, among other tests.
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback